Clinical studies are an essential part of biopharmaceutical research on the journey to discover, develop and deliver new solutions to people living with severe diseases. This Clinical Trial Awareness week, UCB thanks all of the participants in UCB studies and the dedicated researchers doing this important work.

Mental health is top of mind at UCB as we work to prioritize the well-being of our people and the patients we serve. A core pillar of our sustainable business approach, we understand that delivering innovative solutions for patients begins with supporting the physical, mental, and social well-being of our employees, their families, and communities, now and in the future. This Mental Health Awareness Month, learn how we’re supporting mental wellness for our people, patients, and our purpose. 

UCB congratulates Kerry Black, Head of Early Solutions U.S. Operations, and Brooke Fleming, Head of Omnichannel Marketing and Digital Enablement, for their recognition by the Healthcare Businesswomen's Association (HBA) as 2022 Luminary and Rising Star, respectively. 

UCB recently announced the funding recipients for the UCB Community Health Fund’s 2021 call for projects, focused on the needs of vulnerable young people in the wake of COVID-19. Three U.S.-based organizations will receive support from the Fund for projects addressing the mental health of vulnerable young people. 

With nearly 30 years of experience in epilepsy, UCB can and will unlock what's possible for the millions of people living with epilepsy, so their reality can be free from seizures and the other debilitating and unpredictable impacts of the disease. Hear from Mike Davis, Head of U.S. Neurology and Rare, share our plan to impact the underlying causes of the disease and to discover, develop, and deliver highly differentiated medicines that will transform and, ultimately, cure the disease, so that people living with epilepsy can live their ideal life, every day.